|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Veno occlusive disease: Update on clinical management显示文摘Hepatic veno-occlusive disease is a clinical syndrome characterized by hepatomegaly, ascites, weight gain and jaundice, due to sinusoidal congestion which can be caused by alkaloid ingestion, but the most frequent cause is haematopoietic stem cell transplantation (STC) and is also seen after solid organ transplantation. The incidence of veno occlusive disease (VOD) after STC ranges from 0 to 70%, but is decreasing. Survival is good when VOD is a mild form, but when it is severe and associated with an increase of hepatic venous pressure gradient > 20 mmHg, and mortality is about 90%. Prevention remains the best therapeutic strategy, by using non-myeloablative conditioning regimens before STC. Prophylactic administration of ursodeoxycholic acid, being an antioxidant and antiapoptotic agent, can have some benefit in reducing overall mortality. Defibrotide, which has pro-fibrinolytic and antithrombotic properties, is the most effective therapy; decompression of the sinusoids by a transjugular intrahepatic portosystemic shunt (TIPS) can be tried, especially to treat VOD after liver transplantation and when multiorgan failure (MOF) is not present. Liver transplantation can be the last option, but can not be considered a standard rescue therapy, because usually the concomitant presence of multiorgan failure contraindicates this procedure. | M Senzolo G Germani E Cholongitas P Burra AK Burroughs | 2007 | World Journal of Gastroenterology2007，13，29： | 19 |
| 2 | Transarterial chemoembolization and bland embolization for hepatocellular carcinoma显示文摘Transarterial chemoembolization(TACE)is the first line treatment for patients with intermediate stage hepatocellular carcinoma but is also increasingly being used for patients on the transplant waiting list to prevent further tumor growth.Despite its widespread use,TACE remains an unstandardized procedure,with variation in type and size of embolizing particles,type and dose of chemotherapy and interval between therapies.Existing evidence from randomized controlled trials suggest that bland transarterial embolization(TAE)has the same efficacy with TACE.In the current article,we review the use of TACE and TAE for hepatocellular carcinoma and we focus on the evidence for their use. | Emmanuel A Tsochatzis Evangelia Fatourou James O'Beirne Tim Meyer Andrew K Burroughs | 2014 | World Journal of Gastroenterology2014，20，12： | 18 |
| 3 | New insights into the coagulopathy of liver disease and liver transplantation显示文摘The liver is an essential player in the pathway of coagulation in both primary and secondary haemostasis. Only von Willebrand factor is not synthetised by the liver, thus liver failure is associated with impairment of coagulation. However, recently it has been shown that the delicate balance between pro and antithrombotic factors synthetised by the liver might be reset to a lower level in patients with chronic liver disease. Therefore, these patients might not be really anticoagulated in stable condition and bleeding may be caused only when additional factors, such as infections, supervene. Portal hypertension plays an important role in coagulopathy in liver disease, reducing the number of circulating platelets, but platelet function and secretion of thrombopoietin have been also shown to be impaired in patients with liver disease. Vitamin K deficiency may coexist, so that abnormal clotting factors are produced due to lack of gamma carboxylation. Moreover during liver failure, there is a reduced capacity to clear activated haemostatic proteins and protein inhibitor complexes from the circulation. Usually therapy for coagulation disorders in liver disease is needed only during bleeding or before invasive procedures. When end stage liver disease occurs, liver transplantation is the only treatment available, which can restore normal haemostasis, and correct genetic clotting defects, such as haemophilia or factor V Leiden mutation. During liver transplantation haemorrage may occur due to the pre-existing hypocoagulable state, the collateral circulation caused by portal hypertension and increased fibrinolysis which occurs during this surgery. | M Senzolo P Burra E Cholongitas AK Burroughs | 2006 | World Journal of Gastroenterology2006，12，48： | 12 |
| 4 | Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference显示文摘 | Jordi Bruix Morris Sherman Josep M Llovet Michel Beaugrand Riccardo Lencioni Andrew K Burroughs Erik Christensen Luigi Pagliaro Massimo Colombo Juan Rodés | 2001 | Journal of Hepatology2001，，3： | 11 |
| 5 | Liver cirrhosis显示文摘 | Emmanuel A Tsochatzis Jaime Bosch Andrew K Burroughs | 2014 | The Lancet2014，，： | 9 |
| 6 | Adipokines levels are associated with the severity of liver disease in patients with alcoholic cirrhosis显示文摘AIM:To investigate the adipokine levels of leptin,adiponectin,resistin,visfatin,retinol-binding protein 4(RBP4),apelin in alcoholic liver cirrhosis(ALC).METHODS:Forty non-diabetic ALC patients[median age:59 years,males:35(87.5%),Child-Pugh(CP)score:median 7(5-12),CP A/B/C:18/10/12,Model for End-stage Liver Disease(MELD):median 10(6-25),follow-up:median 32.5 mo(10-43)]were prospectively included.The serum adipokine levels were estimated in duplicate by ELISA.Somatometric characteristics were assessed with tetrapolar bioelectrical impedance analysis.Pearson’s rank correlation coefficient was used to assess possible associations with adipokine levels.Univariate and multivariate Cox regression analysis was used to determine independent predictors for overallsurvival.RESULTS:Body mass index:median 25.9(range:20.1-39.3),fat:23.4%(7.6-42.1),fat mass:17.8(5.49-45.4),free fat mass:56.1(39.6-74.4),total body water(TBW):40.6(29.8-58.8).Leptin and visfatin levels were positively associated with fat mass(P<0.001/P=0.027,respectively)and RBP4 with TBW(P=0.025).Median adiponectin levels were significantly higher in CPC compared to CPA(CPA:7.99±14.07,CPB:7.66±3.48,CPC:25.73±26.8,P=0.04),whereas median RBP4 and apelin levels decreased across the spectrum of disease severity(P=0.006/P=0.034,respectively).Following adjustment for fat mass,visfatin and adiponectin levels were significantly increased from CPA to CPC(both P<0.001),whereas an inverse correlation was observed for both RBP4 and apelin(both P<0.001).In the multivariate Cox regression analysis,only MELD had an independent association with overall survival(HR=1.53,95%CI:1.05-2.32;P=0.029).CONCLUSION:Adipokines are associated with deteriorating liver function in a complex manner in patients with alcoholic liver cirrhosis. | Maria Kalafateli Christos Triantos Emmanuel Tsochatzis Marina Michalaki Efstratios Koutroumpakis Konstantinos Thomopoulos Venetsanea Kyriazopoulou Eleni Jelastopulu Andrew Burroughs Chryssoula Lambropoulou-Karatza Vasiliki Nikolopoulou | 2015 | World Journal of Gastroenterology2015，21，10： | 8 |
| 7 | Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions显示文摘 | Luigi Bolondi Andrew Burroughs Jean-Fran?ois Dufour Peter Galle Vincenzo Mazzaferro Fabio Piscaglia Jean Raoul Bruno Sangro | 2012 | Semin Liver Dis2012，，04： | 7 |
| 8 | Anti-tumour necrosis factor agent and liver injury:literature review,recommendations for management显示文摘Abnormalities in liver function tests,including transient and self-limiting hypertransaminasemia,cholestatic disease and hepatitis,can develop during treatment with anti-tumour-necrosis-factor(TNF)therapy.The optimal management of liver injury related to antiTNF therapy is still a matter of debate.Although some authors recommend discontinuing treatment in case of both a rise of alanine aminotransferase more than5 times the upper limit of normal,or the occurrence of jaundice,there are no standard guidelines for the management of anti-TNF-related liver injury.Bibliographical searches were performed in Pub Med,using the following key words:inflammatory bowel disease(IBD);TNF inhibitors;hypertransaminasemia;drugrelated liver injury;infliximab.According to published data,elevation of transaminases in patients with IBD treated with anti-TNF is a common finding,but resolution appears to be the usual outcome.Anti-TNF agents seem to be safe with a low risk of causing severe drugrelated liver injury.According to our centre experience,we found that hypertransaminasemia was a common,mainly self-limiting finding in our IBD cohort and was not correlated to infliximab treatment on both univariate and multivariate analyses.An algorithm for the management of liver impairment occurring during antiTNF treatment is also proposed and this highlights the need of a multidisciplinary approach and suggests liver biopsy as a key-point in the management decision in case of severe rise of transaminases.However,hepatic injury is generally self-limiting and drug withdrawal seems to be an exception. | Roberta Elisa Rossi Ioanna Parisi Edward John Despott Andrew Kenneth Burroughs James O'Beirne Dario Conte Mark Ian Hamilton Charles Daniel Murray | 2014 | World Journal of Gastroenterology2014，20，46： | 7 |
| 9 | Hepatocellular carcinoma显示文摘 | Josep M Llovet Andrew Burroughs Jordi Bruix | 2003 | The Lancet2003，，9399： | 6 |
| 10 | Elastography for the diagnosis of severity of fibrosis in chronic liver disease: A meta-analysis of diagnostic accuracy显示文摘 | E.A. Tsochatzis K.S. Gurusamy S. Ntaoula E. Cholongitas B.R. Davidson A.K. Burroughs | 2010 | Journal of Hepatology2010，，4： | 5 |
| 11 | Factors That Predict Response of Patients With Hepatitis C Virus Infection to Boceprevir显示文摘 | Fred Poordad Jean–Pierre Bronowicki Stuart C. Gordon Stefan Zeuzem Ira M. Jacobson Mark S. Sulkowski Thierry Poynard Timothy R. Morgan Cliona Molony Lisa D. Pedicone Heather L. Sings Margaret H. Burroughs Vilma Sniukiene Navdeep Boparai Venkata S. Goteti | 2012 | Gastroenterology2012，，3： | 5 |
| 12 | Hepatocellular carcinoma显示文摘 | Josep M Llovet Andrew Burroughs Jordi Bruix | 2003 | The Lancet2003，，9399： | 4 |
| 13 | International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis显示文摘 | F. Alvarez P.A. Berg F.B. Bianchi L. Bianchi A.K. Burroughs E.L. Cancado R.W. Chapman W.G.E. Cooksley A.J. Czaja V.J. Desmet P.T. Donaldson A.L.W.F. Eddleston L. Fainboim J. Heathcote J.-C. Homberg J.H. Hoofnagle S. Kakumu E.L. Krawitt I.R. Mackay R.N.M. | 1999 | Journal of Hepatology1999，，5： | 4 |
| 14 | Liver grafts from anti-hepatitis B core positive donors: A systematic review显示文摘 | Evangelos Cholongitas George V. Papatheodoridis Andrew K. Burroughs | 2009 | Journal of Hepatology2009，，2： | 4 |
| 15 | Hepatocellular carcinoma显示文摘 | Josep M Llovet Andrew Burroughs Jordi Bruix | 2003 | The Lancet2003，，9399： | 4 |
| 16 | Renal failure and cirrhosis: A systematic review of mortality and prognosis显示文摘 | Giuseppe Fede Gennaro D’Amico Vasiliki Arvaniti Emmanuel Tsochatzis Giacomo Germani Dimosthenis Georgiadis Alberto Morabito Andrew Kenneth Burroughs | 2011 | Journal of Hepatology2011，，4： | 4 |
| 17 | Can non-invasive measurements aid clinical assessment of volume in patients with cirrhosis?显示文摘AIM:To evaluate the non-invasive assessments of volume status in patients with cirrhosis.METHODS:Echocardiography and multifrequency bioimpedance analysis measurements and short synacthen tests were made in 20 stable and 25 acutely decompensated patients with cirrhosis.RESULTS:Both groups had similar clinical assessments,cortisol response and total body water(TBW),however the ratio of extracellular water(ECW)/TBW was significantly greater in the trunk(0.420±0.004 vs0.404±0.005),and limbs(R leg 0.41±0.003 vs 0.398±0.003,P<0.05,and L leg 0.412±0.003 vs 0.399±0.003)with decompensated cirrhosis compared to stable cirrhotics,P<0.05).Echocardiogram derived right atrial and ventricular filling and end diastolic pressures and presence of increased left ventricular end diastolic volume and diastolic dysfunction were similar in both groups.The decompensated group had lower systemic blood pressure,mean systolic 101.8±4.3 vs122.4±5.3 and diastolic 58.4±4.1 mmHg vs 68.8±3.1 mmHg respectively,P<0.01,and serum albumin30(27-33)vs 32(31-40.5)g/L,P<0.01.CONCLUSION:Decompensated cirrhotics had greater leg and truncal ECW expansion with lower serum albumin levels consistent with intravascular volume depletion and increased vascular permeability. | Andrew Davenport Banwari Argawal Gavin Wright Konstantinos Mantzoukis Rumyana Dimitrova Joseph Davar Panayota Vasianopoulou Andrew K Burroughs | 2013 | World Journal of Hepatology2013，5，8： | 3 |
| 18 | 猪痢疾发病机理及诊断技术研究进展显示文摘猪痢疾是以出血性黏液样腹泻为特征的一种严重的肠道疾病。该疾病是由短螺旋体感染引起的,最常见于生长育肥猪。易感猪主要以黏膜出血性盲肠结肠炎为主要临床特征,严重的可以引起死亡,即使恢复健康后也会降低生长性能,给养殖业造成严重的经济损失。本文综述了猪痢疾的病因、发病机制和诊断知识,以期为该病的风险防控提供科学依据。 | Burrough ER 刘河冰 | 2018 | 中国猪业2018，13，5： | 3 |
| 19 | Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis显示文摘 | Cristina Ripoll Roberto J. Groszmann Guadalupe Garcia-Tsao Jaime Bosch Norman Grace Andrew Burroughs Ramon Planas Angels Escorsell Juan Carlos Garcia-Pagan Robert Makuch David Patch Daniel S. Matloff | 2009 | Journal of Hepatology2009，，5： | 3 |
| 20 | EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization显示文摘 | Roopinder Gillmore Sam Stuart Amy Kirkwood Ayshea Hameeduddin Nick Woodward Andrew K. Burroughs Tim Meyer | 2011 | Journal of Hepatology2011，，6： | 3 |
您所在的机构暂未开通此部分的功能，请联系管理员